

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)



(10) International Publication Number
WO 2023/036961 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 31/7088* (2006.01)
A61K 9/08 (2006.01) *A61K 47/02* (2006.01)
A61K 31/7105 (2006.01) *A61K 47/12* (2006.01)
A61P 1/04 (2006.01) *A61K 47/14* (2017.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2022/075174

(22) International Filing Date:

09 September 2022 (09.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21275126.7 09 September 2021 (09.09.2021) EP

(71) Applicant: **INDEX PHARMACEUTICALS AB**

[SE/SE]; Berzelius väg 13, 171 65 Solna (SE).

(72) Inventors: **CORONA, Franziska Müller**; Röserstrasse 72, 4402 Frenkendorf (CH). **WANNER, Ralf**; Brunnmatenweg 12, 79599 Wittlingen (DE). **DATHE, Britta**; Ob dem Fichtenrain 12, 4106 Therwil (CH). **SANDWALL, Pernilla Helena**; Virvelvindsvägen 4, 167 67 Bromma (SE). **JOHANSSON, Christine Dieterich**; Örtagårdsvägen 18, 186 50 Vallentuna (SE). **ALHADEFF, Paul**; Övrasjövägen 5, 147 63 Uttran (SE).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London Greater London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ENEMA FORMULATION

(57) Abstract: The present invention provides an aqueous formulation suitable for rectal administration comprising (i) an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCATGGC-3' (SEQ ID NO:2), (ii) at least one preservative and (iii) a buffer comprising citric acid and a phosphate salt.

WO 2023/036961 A1